Crossmark

Minimal residual disease-directed immunotherapy for high-risk myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation

Published Online: 2019-06-11

Published Print: 2019-06

Authors

Mo, Xiaodong

Zhang, Xiaohui

Xu, Lanping

Wang, Yu

Yan, Chenhua

Chen, Huan

Chen, Yuhong

Han, Wei

Wang, Fengrong

Wang, Jingzhi

Liu, Kaiyan

Huang, Xiaojun
License Information

Text and Data Mining valid from 2019-06-01

Version of Record valid from 2019-06-01
More Information

Article History

Received: 7 January 2018

Accepted: 26 June 2018

First Online: 11 June 2019

Document is current